why is compound semaglutide not fda approved moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to drugs and signaling stronger enforcement to protect patients from unverified Compound versions of GLP-1 drugs

Patients should rotate injection sites (abdomen, thigh, or upper arm), allow the medication to reach room temperature before injection, and ensure proper technique

The FDA declared in February 2025 that the supply issues for both Ozempic and Wegovy have been resolved, reducing the need for compounded alternatives

Users restarting after a break should also review our guide on restarting semaglutide to understand how missed doses during travel may affect re-titration

These findings suggest that GLP-1RA users may face a higher risk of inadequate screening results, which can diminish diagnostic accuracy and compromise patient safety

This gradual approach is not arbitrary